SMMT — Summit Therapeutics Share News
0.000.00%
Last trade - 00:00- $10.87bn
- $10.28bn
Brief: Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors
Focus: US pharma bets big on China to snap up potential blockbuster drugs
U.S. STOCKS ON THE MOVE-Caterpillar, Starbucks, Lockheed Martin
U.S. STOCKS ON THE MOVE-Vaxart, DoubleVerify, Cracker Barrel
U.S. STOCKS ON THE MOVE-MP Materials, Ouster, Tesla
U.S. STOCKS ON THE MOVE-Quantum computing stocks, Grab Holdings, Talen Energy
Summit slips as Leerink doubts cancer drug can match Keytruda's success
BioNTech climbs on cancer drug deal with Bristol Myers
U.S. STOCKS ON THE MOVE-RBB Bancorp, Seacoast, GATX
U.S. STOCKS ON THE MOVE-Nordson, Regeneron, Gap Inc
Summit Therapeutics falls after mixed data from late-stage cancer trial
U.S. STOCKS ON THE MOVE-Tesla, Apple, Airbnb
Summit Therapeutics falls after mixed data from late-stage cancer trial
Brief: Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Summit Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Summit Therapeutics Q1 Net Income USD -62.9 Million
Summit Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Summit Therapeutics closes 36% lower after interim data for cancer drug
Summit Therapeutics gains as lung cancer drug succeeds in second study in China